Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?

Best practice & research. Clinical haematology - 1 Sept 2017

Short Nicholas J, Kantarjian Hagop, Jabbour Elias, Ravandi Farhad

Abstract excerpt

The incorporation of tyrosine kinase inhibitors (TKIs) into chemotherapy regimens has significantly improved the long-term survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Successive generations of TKIs with increased potency against BCR-ABL and broader spectrum of activity against ABL kinase domain mutations have led to incremental improvements in the outcomes of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pyridazines
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Imidazoles

Share to Philadelphia Chromosome

Share to Transplantation, Homologous

Source

Identifiers

PMID: 29050692
DOI: 10.1016/j.beha.2017.05.001

Genes

BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?PMID 29050692Read ↗

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?Semantic proximity Read ↗

How has the management of Ph+ acute lymphoblastic leukemia (ALL) changed over the years.Semantic proximity Read ↗

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in AdultsSemantic proximity Read ↗

Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemiaSemantic proximity Read ↗

Management of adult Ph-positive acute lymphoblastic leukemia.Semantic proximity Read ↗

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasSemantic proximity Read ↗

Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic AnemiaSemantic proximity Read ↗

Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.Semantic proximity Read ↗

Ponatinib in refractory Philadelphia chromosome-positive leukemias.Semantic proximity Read ↗

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome‐positive adult acute lymphoblastic leukemiaSemantic proximity Read ↗

Ph+ ALL: new approaches for upfront therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.